Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry co...
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled ...
Sanofi-Aventis, Alger, Algeria
CHU Angers, Service d'hépato-gastroentérologie, Angers, France
Sanofi-Aventis, Istanbul, Turkey
Sanofi-Aventis, Taipei, Taiwan
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Population Health Research Institute of McMaster University, Hamilton, Ontario, Canada
Novartis Pharmaceuticals, Basel, Switzerland
Institute of Clinical Pharmacology, Medical Faculty, University of Technology, Dresden, Germany
CRC, Medizinsiche Klinik 4, Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Bavaria, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.